Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesHeron Therapeutics Inc.

Heron Therapeutics Inc.

PortfolioPortfolio WatchlistWatchlist
Company price
0.2903 GBX -0.01 ( 3.23%)
Last update at 2026-10-26T14:11:00Z
VOLUME
1790
Market Cap
6766.62M

Momentum Score

…

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.28
Low
0.29
High
52 Week Price Range
0.75
Low
2.61
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.30
Dividend Yield
-
Revenue TTM
154.90M
Revenue Per Share
0.93
Gross Profit TTM
112.52M
Debt / Equity
9.81
ROE
-2408.88%
Net Debt
111.99M
ROCE
-0.44%
Diluted EPS TTM
-2.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -20.20M -13.58M -110.56M -182.02M -220.68M
Net income -20.20M -13.58M -110.56M -182.02M -220.68M
Selling general administrative - 53.40M 41.71M 37.24M 40.15M
Selling and marketing expenses - 47.09M 61.34M 81.51M 86.98M
Gross profit 113.56M 105.64M 10.04M -50.51M -89.30M
Ebit -2.54M -7.55M -106.69M -169.26M -216.43M
Ebitda -0.22M -5.06M -103.79M -166.37M -213.41M
Depreciation and amortization 2.31M 2.49M 2.90M 2.89M 3.02M
Operating income -2.54M -11.53M -110.61M -169.26M -216.43M
Other operating expenses 157.44M 155.81M 237.66M 288.86M 305.05M
Interest expense 9.61M 6.03M 3.87M - 0.00M
Income tax expense - - 17.60M - -
Total revenue 154.90M 144.28M 127.04M 107.67M 86.35M
Total operating expenses 116.09M 117.17M 120.66M 130.68M 129.41M
Cost of revenue 41.35M 38.65M 117.00M 158.18M 175.64M
Total other income expense net -17.66M -2.05M 0.06M -12.77M -4.25M
Net income applicable to common shares - - - -182.02M -220.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 670.88M 233.15M 222.51M 250.95M 305.71M
Other current assets 9.10M 17.69M 6.12M 13.96M 12.96M
Total liab 656.54M 266.80M 256.48M 237.38M 228.14M
Total stockholder equity 14.33M -33.65M -33.97M 13.57M 77.57M
Other current liab 87.10M 73.67M 73.37M 79.13M 67.25M
Common stock 1.88M 1.52M 1.50M 1.19M 1.02M
Retained earnings -1939.79M -1919.59M -1906.01M -1795.45M -1613.43M
Other liab - - - 0.24M -
Other assets - 0.00M - 15.71M 17.72M
Cash 28.65M 25.80M 28.68M 15.36M 90.54M
Total current liabilities 96.10M 91.46M 79.69M 82.36M 71.06M
Current deferred revenue - - -3.08M - -
Net debt 111.99M 151.96M 150.95M -15.36M -90.54M
Short term debt - 6.07M 3.08M - -
Short long term debt total 140.64M 177.76M 179.63M - -
Other stockholder equity 1951.18M 1884.41M 1870.53M 1807.84M 1689.98M
Property plant equipment - - - 29.80M 33.56M
Total current assets 238.07M 209.01M 188.77M 205.44M 254.42M
Net tangible assets - - - 13.57M 77.57M
Short term investments 17.98M 33.48M 51.73M 69.49M 67.04M
Net receivables 89.59M 78.88M 60.14M 52.05M 35.50M
Inventory 92.75M 53.16M 42.11M 54.57M 48.38M
Accounts payable 8.99M 11.71M 3.24M 3.23M 3.80M
Accumulated other comprehensive income 0.00M 0.01M 0.01M - -
Non currrent assets other 5.41M 6.48M 8.13M -29.80M -33.56M
Non current assets total 432.81M 24.13M 33.73M 29.80M 33.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - -1.73M 35.72M
Change to liabilities - - - -0.58M 3.28M
Total cashflows from investing activities 16.01M 18.71M 18.00M -3.32M 32.73M
Net borrowings - - - - 148.96M
Total cash from financing activities 14.43M 0.94M 54.11M 75.06M 156.03M
Change to operating activities - - - 12.81M -38.23M
Net income -20.20M -13.58M -110.56M -182.02M -220.68M
Change in cash 2.85M -2.88M 13.31M -75.18M -14.60M
Begin period cash flow 25.80M 28.68M 15.36M 90.54M 105.14M
End period cash flow 28.65M 25.80M 28.68M 15.36M 90.54M
Total cash from operating activities -27.59M -22.53M -58.79M -146.91M -203.35M
Depreciation 2.31M 2.49M 2.90M 2.89M 3.02M
Other cashflows from investing activities - - 19.54M - -
Change to inventory -31.05M -11.05M 12.46M -6.19M -6.48M
Change to account receivables -10.71M -18.74M -8.09M -16.55M 6.35M
Other cashflows from financing activities -150.00M - 29.76M 75.06M 156.03M
Change to netincome - - - 42.53M 48.48M
Capital expenditures 0.32M 1.71M 1.54M 1.82M 3.02M
Change in working capital -31.88M -27.60M 16.77M -22.74M -0.13M
Stock based compensation - - 32.85M 42.98M 46.85M
Other non cash items 22.17M 16.16M 33.50M 11.98M -32.42M
Free cash flow -27.91M -24.23M -60.33M -148.74M -206.38M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0J4V
Heron Therapeutics Inc.		 -0.01
3.23%		 0.29 - - 0.44 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Heron Therapeutics Inc.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

100 Regency Forest Drive, Cary, NC, United States, 27518

858 251 4400

https://www.herontx.com

128

Name Title Year Born
Dr. Barry D. Quart Pharm.D. Chairman & CEO 1957
Mr. John W. Poyhonen Pres & Chief Commercial Officer 1960
Mr. David L. Szekeres Exec. VP & COO 1974
Ms. Lisa Peraza VP & Chief Accounting Officer 1977
Ms. Kimberly J. Manhard Exec. VP of Drug Devel. & Director 1960
Mr. Sean T. Ristine Sr. VP of HR 1970
Dr. Thomas B. Ottoboni Ph.D. Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences 1959
Mr. Michael E. Mathews Sr. VP of Acute Care 1963
Dr. Chris M. Storgard Chief Medical Officer 1966
Mr. Craig Alexander Collard CEO & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…